Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 18 years and over~* Able and willing (in the Investigator's opinion) to comply with all study requirements~* Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner~* For heterosexual, pre-menopausal females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day of vaccination~* Agreement to refrain from blood donation during the course of the study~* Provide written informed consent~Exclusion Criteria:~* Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period~* Prior receipt of an investigational influenza vaccine, or any other investigational vaccine likely to impact on interpretation of the trial data.~* Receipt of the 2013/14 seasonal influenza vaccine prior to entering the study.~* Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate~* Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids are allowed)~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products~* Any history of anaphylaxis in reaction to vaccination~* Recent treatment for cancer (except basal cell carcinoma and cervical carcinoma in situ)~* History of a serious psychiatric condition~* Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week)~* Seropositive for hepatitis B surface (HBsAg) or hepatitis C virus (antibodies to HCV) For pre-menopausal females, pregnancy, lactation or willingness/intention to become pregnant during the study~* Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study.~* No response / confirmation from GP regarding previous medical history

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Viroflu® and MVA-NP+M1 (Type: EXPERIMENTAL): 1 dose (0.5ml) of Viroflu® and 1 dose of 1.5 x10\^8 pfu MVA-NP+M1 intramuscularly into the vastus lateralis muscle on day 0. The vaccines will be given side by side, with MVA NP+M1 being given immediately after the seasonal influenza vaccine.
- Viroflu® and saline placebo (Type: PLACEBO_COMPARATOR): 1 dose (0.5ml) of Viroflu® and 1 dose of a 0.9% saline placebo injected intramuscularly into the vastus lateralis muscle on day 0. The placebo will be administered immediately after the seasonal influenza vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy